CD79B 靶点蛋白|抗体药物|临床药物信息

CD79B信息

英文名称：B-cell antigen receptor complex-associated protein beta chain
中文名称：B细胞抗原受体复合物相关蛋白β链
靶点别称：B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6

上市药物数量：1
临床药物数量：2
最高研发阶段：批准上市

CD79B产品列表

筛选结果

产品库

物种

标签

属性

Protein (9)

标记

货号	物种	产品描述
CDB-H5259	Human	Human CD79B Protein, Fc Tag
CDB-C52H3	Cynomolgus	Cynomolgus CD79B Protein, His Tag (MALS verified)
CDB-M52H4	Mouse	Mouse CD79B Protein, His Tag, low endotoxin (MALS verified)
CDB-M52H3	Mouse	Mouse CD79B Protein, His Tag (MALS verified)
CDB-H82E3	Human	Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified)
CDB-H52H3	Human	Human CD79B Protein, His Tag (MALS verified)
CDB-M5253	Mouse	Mouse CD79B Protein, Fc Tag
CDB-C82E5	Cynomolgus	Biotinylated Cynomolgus CD79B Protein, His,Avitag™
CDB-HP2H6	Human	PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation)

CD79B 分子别名

CD79b,B29,IGB,Ig-beta

CD79B 分子背景

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

CD79B 前沿进展

CD79B上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Polatuzumab vedotin	维博妥珠单抗	RG-7596; RO-5541077; RO-5541077-000; FCU-2711; DCDS-4501A	批准上市	基因泰克, Seattle Genetics	Polivy	Japan	弥漫性大B-细胞淋巴瘤	F. Hoffmann-La Roche Ag	2019-06-10	B-细胞淋巴瘤, 弥漫性大B-细胞淋巴瘤, 滤泡中心淋巴瘤, 非霍奇金淋巴瘤	详情

CD79B临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
NBT-508		临床一期	上海新理念生物医药科技有限公司	B-细胞淋巴瘤, 非霍奇金淋巴瘤	详情
PRV-3279	MGD-010; PRV-3279; CD32BxCD79B	临床二期	Macrogenics	药物相关的副作用和不良反应	详情

会议日历

会议一览

CD79B